Global disease experts say little is known about China's experience with long-term COVID effects thought to have afflicted millions with debilitating fatigue, brain fog and other symptoms
Chinese producers agree to supply more than half a billion vaccines to COVAX
The GAVI alliance said on Monday it had signed two advance purchase agreements with Chinese drugmakers Sinopharm and Sinovac to provide up to 550 million COVID-19 vaccines to the COVAX programme.
Published : 12 July 2021, 10:36 AM
Updated : 12 July 2021, 10:36 AM
The new deals include up to 170 million doses of the Sinopharm shot and up to 380 million doses of the Sinovac vaccine, through to the middle of 2022, the statement said. Sinovac confirmed the agreement in a statement.
"The agreements, which come at a time when the Delta variant is posing a rising risk to health systems, will begin to make 110 million doses immediately available to participants of the COVAX Facility, with options for additional doses," GAVI said in a statement.
COVAX, which distributes vaccines to poorer countries, has struggled to meet its early commitments amid Indian export disruptions, forcing many countries to freeze their inoculation programmes in their early phases.
However, its latest supply forecast shows that the programme is on track to deliver more than 2 billion doses by early 2022.
RELATED STORIES
The demonstrations helped to end COVID restrictions but failed to achieve lasting political change, six participants based in China and overseas say
The agency seeks details on an increase in respiratory illnesses and reported clusters of pneumonia in children, which its China office called a ‘routine’ check
The inquiry is examining the government's response to the coronavirus pandemic that shut large sections of the economy and killed more than 220,000 people in Britain
